Siren Interactive Expands Services with Online Clinical Trial Recruitment Acceleration
/EINPresswire.com/ Oak Park, IL (April 5, 2012) - Siren Interactive, a digital agency focused on rare disorders, has expanded its service offerings to include online clinical trial recruitment acceleration to help biopharmaceutical companies studying new medicines for rare diseases.
In the US, a disease is considered rare if it affects fewer than 200,000 Americans. There are approximately 7,000 such diseases, and the Food and Drug Administration (FDA) has approved treatments for about 380 rare disorders, or 5 percent. Because finding information about rare disorder diagnosis, treatment and physician specialists is more challenging than it would be for a more common disease, rare disease patients and caregivers rely more heavily on the Internet for disease information and peer support.
"The key challenge for rare disease clinical trials is finding patients. At Siren, we excel at finding rare disease patients and caregivers during the commercialization phase. We're now using this expertise earlier in the process," noted Wendy White, founder and president of Siren Interactive. "MicroTargetingSM is at the core of our process of designing focused campaigns that reach patients where they are most likely to be receptive to information about participating in clinical trials."
Recruiting qualified participants for a rare disease therapy clinical trial can be especially challenging, since it's possible that the total global patient population for a rare disorder is only a few thousand patients. White will be delivering a presentation on the value of MicroTargetingSM in clinical trial recruitment acceleration using social media on Thursday, April 12, at the World Orphan Drug Congress in Washington, DC.
About Siren Interactive
Siren Interactive is focused on understanding the behaviors of patients and physicians dealing with chronic rare diseases. Because of this expertise, the agency can drive new patient starts and lifelong adherence to therapies for its clients. A recipient of the 2011 Manny Heart Award, Siren Interactive is the nation's first and only marketing agency with dual regulatory compliance certification for Patient Relationship Marketing and Internet Promotion/Social Media. The agency was founded in 1999 as a woman-owned business and has been on the Inc. 5000 list of the fastest-growing private companies in the US for the past two years. For more information, visit http://www.sireninteractive.com.
Media Contact:
Chuck Strand
708-434-6271
cstrand@sireninteractive.com
In the US, a disease is considered rare if it affects fewer than 200,000 Americans. There are approximately 7,000 such diseases, and the Food and Drug Administration (FDA) has approved treatments for about 380 rare disorders, or 5 percent. Because finding information about rare disorder diagnosis, treatment and physician specialists is more challenging than it would be for a more common disease, rare disease patients and caregivers rely more heavily on the Internet for disease information and peer support.
"The key challenge for rare disease clinical trials is finding patients. At Siren, we excel at finding rare disease patients and caregivers during the commercialization phase. We're now using this expertise earlier in the process," noted Wendy White, founder and president of Siren Interactive. "MicroTargetingSM is at the core of our process of designing focused campaigns that reach patients where they are most likely to be receptive to information about participating in clinical trials."
Recruiting qualified participants for a rare disease therapy clinical trial can be especially challenging, since it's possible that the total global patient population for a rare disorder is only a few thousand patients. White will be delivering a presentation on the value of MicroTargetingSM in clinical trial recruitment acceleration using social media on Thursday, April 12, at the World Orphan Drug Congress in Washington, DC.
About Siren Interactive
Siren Interactive is focused on understanding the behaviors of patients and physicians dealing with chronic rare diseases. Because of this expertise, the agency can drive new patient starts and lifelong adherence to therapies for its clients. A recipient of the 2011 Manny Heart Award, Siren Interactive is the nation's first and only marketing agency with dual regulatory compliance certification for Patient Relationship Marketing and Internet Promotion/Social Media. The agency was founded in 1999 as a woman-owned business and has been on the Inc. 5000 list of the fastest-growing private companies in the US for the past two years. For more information, visit http://www.sireninteractive.com.
Media Contact:
Chuck Strand
708-434-6271
cstrand@sireninteractive.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.